Rubicon’s well designed and well equipped R&D labs and manufacturing facilities offers an ideal one-stop shop for its partners.


Rubicon operates out of three locations

1. Rubicon Corporate HQ and R&D Center – Thane

Recently commissioned, the 38,000 sq ft facility will focus initially on formulation development and drug product analytical development including a dedicated high potency suite. This new R&D at Rubicon operates out of a modern facility based in Thane, India. The R&D team comprises of about 150 scientists and technical staff engaged in all aspects of pharmaceutical research i.e. formulation development, analytical development, packaging development, clinical and bioequivalence studies, intellectual property management and regulatory affairs. The R&D Center develops products, Proof of Concepts and novel technologies spread across various therapeutic areas and dosage forms.


Rubicon’s R&D center has three formulation facilities

1. General Category Facility to support

  • Oral Solids : -
    • - Tablets:- Immediate Release ,Sustained Release, Delayed-Release, Controlled Release, Film Coated, Enteric-coated tablets
    • - Capsules: - Powders, Granules, Pellets
    • - Powders:- Sachets, Direct-to-mouth, Powder for Suspension
  • Oral Liquids : -
    • Syrups, Solutions, Suspensions, Complex Modified
    • Release multi ingredient suspension,
    • Penn-kinetic technology know-how, ion exchange complexation
  • Topical: -
    • Creams, Ointments, Gels, Lotions

2. Sterile Facility to support

  • Ophthalmic: -
    • Solution, Suspensions
  • Injections: -
    • Liquid Injections, Lyophilized

3. Development Facility for handling High Potency Compounds

    • OEL category 4 and 5 compounds A dedicated and self-contained formulation laboratory incorporates pressure gradients facilitating containment of particles, single pass air system in the area, reverse laminar airflow and personal protective equipment (PPEs) for protection of personnel, decontamination area of material and garments.

    • The R&D team is supported by technical services team and method validation team based at manufacturing site at Ambernath. The product/ technology developed at R&D is scaled up and validated at the Ambernath site to ensure integrated and seamless executed of products for filing and commercialization

Rubicon Research Pvt. Ltd.
MedOne House
Plot No. B-75, Road No. 33,
Wagale Industrial Estate
Thane West 400604

2. Rubicon Manufacturing Site – Ambernath, Thane

Rubicon’s Ambernath Plant supports scale up and
commercialization of Oral Solids

Rubicon has a built up 150,000 sq. ft. state-of-art plant compliant with USFDA and EU specifications with 21,500 sq. ft. (and currently expanding another 43,500 sq ft). of the entire area specially devoted to cGMP manufacturing of Class 100,000. The manufacturing capacity of the plant is as follows

Manufacturing Activity Current Capacity (Million Units) Capacity under Expansion (Million Units)
Compression 1,000 3,000
Coating 800 1,600
Blister Packing 576 1,200
Capsule Filling 700 1,000
Bottle Packing 1,000 1,600

Rubicon Research Pvt. Ltd.
Plot no. K 30/4 & 30/5,
Additional MIDC, Ambernath,
Dist. Thane, Maharashtra, INDIA. Pin: 421 506.
Tel : (0251) 262 1721/3/6.

To request for an equipment list, drop in a mail at bd@rubicon.co.in

3. Business Development and Regulatory Office, Plainsboro, New Jersey

Rubicon’s partners are dominantly U.S. based and Canadian companies and products are routinely submitted to the USFDA, and therefore for ease of doing business, Rubicon has a Business Development and Regulatory Office in New Jersey at the following address

Please feel free to set up an appointment to meet at Rubicon’s New Jersey office to discuss new opportunities and ongoing projects. To set up an appointment, drop in a mail to bd@rubicon.co.in

Rubicon Research Pvt. Ltd.
Suite 605, Princeton Office Center II
666 Plainsboro Road, Plainsboro
New Jersey 08536